{"doi":"10.2217/fon-2022-0802","title":"LITESPARK-011: belzutifan plus lenvatinib vs cabozantinib in advanced renal cell carcinoma after anti-PD-1/PD-L1 therapy","abstract":null,"journal":"Future Oncology","year":2023,"id":633817,"datarank":0.5641800173540344,"base_score":3.7612001156935624,"endowment":3.7612001156935624,"self_citation_contribution":0.5641800173540344,"citation_network_contribution":0.0,"self_endowment_contribution":0.5641800173540344,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":42,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1643506,"name":"Manuela Schmidinger","orcid":null,"position":1,"is_corresponding":false},{"id":1637253,"name":"Masatoshi Eto","orcid":null,"position":2,"is_corresponding":false},{"id":1564716,"name":"Cristina Suarez","orcid":null,"position":3,"is_corresponding":false},{"id":833574,"name":"Robert Figlin","orcid":null,"position":4,"is_corresponding":false},{"id":1214811,"name":"Yanfang Liu","orcid":"0009-0004-5562-6569","position":5,"is_corresponding":false},{"id":1643395,"name":"Rodolfo Perini","orcid":null,"position":6,"is_corresponding":false},{"id":1643507,"name":"Yayan Zhang","orcid":null,"position":7,"is_corresponding":false},{"id":1643508,"name":"Daniel YC Heng","orcid":null,"position":8,"is_corresponding":false},{"id":226686,"name":"Robert J. Motzer","orcid":"0000-0001-6925-2327","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"LITESPARK-011: belzutifan plus lenvatinib vs cabozantinib in advanced renal cell carcinoma after anti-PD-1/PD-L1 therapy","abstract":"The first-in-class, small molecule HIF-2α inhibitor, belzutifan, has demonstrated promising antitumor activity in previously treated patients with clear cell renal cell carcinoma (RCC). HIF-2α also regulates VEGF expression and is involved in resistance to anti-VEGF therapy. This study describes the rationale and design for a randomized, phase III study evaluating efficacy and safety of belzutifan plus the tyrosine kinase inhibitor (TKI) lenvatinib versus the TKI cabozantinib in patients with advanced RCC progressing after anti-PD-1/PD-L1 therapy in the first- or second-line setting or as adjuvant therapy. Considering the unmet need for effective and tolerable treatment of advanced RCC following immune checkpoint inhibitors, belzutifan plus lenvatinib may have a positive benefit/risk profile. Clinical Trial Registration: NCT04586231 (ClinicalTrials.gov)","is_dataset_classified":null,"base_score":3.7376696182833684,"endowment":3.7376696182833684,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"36752726","pmcid":"PMC13248041","openalex_id":"https://openalex.org/W4319460485","authors":[],"funders":[{"funder_name":"NCI NIH HHS","grant_id":"P30 CA008748","title":null},{"funder_name":"Eisai Inc., Nutley NJ USA","grant_id":"","title":null},{"funder_name":"Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ USA","grant_id":"","title":null},{"funder_name":"Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ USA","grant_id":"","title":null}],"total_grants":4,"fwci":6.7623,"citation_percentile":0.97767196,"influential_citations":0,"citation_trend":[{"year":2023,"count":4},{"year":2024,"count":14},{"year":2025,"count":14},{"year":2026,"count":9}],"oa_status":"hybrid","license":"cc-by-nc-nd","oa_locations":[{"url":"https://doi.org/10.2217/fon-2022-0802","host_type":"journal"},{"url":"https://doi.org/10.2217/fon-2022-0802","host_type":"publisher"},{"url":"https://www.tandfonline.com/doi/pdf/10.2217/fon-2022-0802","host_type":"publisher"},{"url":"https://pubmed.ncbi.nlm.nih.gov/36752726","host_type":"repository"},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13248041/","host_type":"repository"},{"url":"https://europepmc.org/articles/PMC13248041","host_type":"Europe_PMC"},{"url":"https://europepmc.org/articles/PMC13248041?pdf=render","host_type":"Europe_PMC"}],"fields_of_study":["Renal cell carcinoma treatment","Cancer Genomics and Diagnostics","Pancreatic and Hepatic Oncology Research"],"mesh_terms":["Anilides","Carcinoma, Renal Cell","Humans","Indenes","Kidney Neoplasms","Phenylurea Compounds","Pyridines","Quinolines","Protein Kinase Inhibitors","Basic Helix-Loop-Helix Transcription Factors","Basic Helix-Loop-Helix Proteins","B7-H1 Antigen"],"keywords":["Cabozantinib","Lenvatinib","Medicine","Renal cell carcinoma","PD-L1","Oncology","Internal medicine","Hepatocellular carcinoma","Sorafenib","Immunotherapy","Cancer","Metastatic","Clear Cell Renal Cell Carcinoma","Immune Checkpoint Inhibitor","Pd-1/pd-l1 Inhibitor","Hif-2α Inhibitor"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[{"name":"nct"}],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-06T12:44:15.567338Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}